• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA
Click for more information
2.50% 20.5¢

PHARMAUST LIMITED - Announcements

Market Cap $82.69M  ! watchlist Created with Sketch. Add to my watchlist

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Announcements


Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PAA Phase I Monepantel Tablets Demonstrate High SafetyPRICE SENSITIVE28/03/19
PAA PharmAust Raises $1.3m in Rights IssuePRICE SENSITIVE22/03/19
PAA MPL Tablets Demonstrate Positive Performance in Phase 1PRICE SENSITIVE14/03/19
PAA PharmAust Rights Issue Reaches Minimum SubscriptionPRICE SENSITIVE12/03/19
PAA PharmAust Intellectual Property Update05/03/19
PAA Appendix 4D & Financial ReportPRICE SENSITIVE01/03/19
PAA Offer Document - Rights IssuePRICE SENSITIVE26/02/19
PAA Phase I Dog Trial with New Monepantel Tablets CommencesPRICE SENSITIVE20/02/19
PAA Letter to Shareholders19/02/19
PAA Epichem Awarded One-Year Contract Extension from DNDiPRICE SENSITIVE18/02/19
PAA Letter to Optionholders18/02/19
PAA Section 708AA Notice18/02/19
PAA Appendix 3B18/02/19
PAA Non-Renounceable Rights OfferPRICE SENSITIVE18/02/19
PAA Appendix 3B - Amendment14/02/19
PAA PAA Completes Successful Taste Mask Testing of New TabletPRICE SENSITIVE11/02/19
PAA Section 708 Notice07/02/19
PAA Appendix 3B07/02/19
PAA PharmAust Signs Agreement for US Phase I Trials in DogsPRICE SENSITIVE07/02/19
PAA PharmAust Completes Scaled Manufacture of Monepantel TabletsPRICE SENSITIVE07/02/19
PAA PharmAust Appendix 4C and Shareholders' UpdatePRICE SENSITIVE31/01/19
PAA PharmAust and Elanco Execute Data Sharing AgreementPRICE SENSITIVE29/01/19
PAA Optimisation of Monepantel UptakePRICE SENSITIVE21/01/19
PAA Monepantel Principal Metabolite Shows Anti-Cancer ActivityPRICE SENSITIVE14/01/19
PAA PharmAust Develops Method for MPL/Analogue ManufacturePRICE SENSITIVE03/12/18
PAA GMP Tablet Manufacture Commences for Canine Clinical TrialsPRICE SENSITIVE13/11/18
PAA Results of Annual General Meeting09/11/18
PAA AGM Presentation09/11/18
PAA Appendix 4C & Company Update - Sep 2018PRICE SENSITIVE01/11/18
PAA PharmAust Develops GMP Method for Monepantel AnaloguesPRICE SENSITIVE29/10/18
PAA PharmAust Progresses Monepantel Tablet Program for CancerPRICE SENSITIVE15/10/18
PAA Notice of Annual General Meeting/Proxy Form10/10/18
PAA Appendix 3X & 3Z08/10/18
PAA Neville Bassett AM appointed to PharmAust Board02/10/18
PAA Appendix 4G & Corporate Governance Statement01/10/18
PAA Annual Report01/10/18
PAA Olivia Newton-John Cancer Reseach Institute collaborationPRICE SENSITIVE10/09/18
PAA Reformulation of MPL into tablet form for upcoming trialsPRICE SENSITIVE04/09/18
PAA Preliminary Final ReportPRICE SENSITIVE03/09/18
PAA Appendix 4C & Company Update - June 18PRICE SENSITIVE31/07/18
PAA Epichem gains prestigious international ISO accreditationPRICE SENSITIVE02/07/18
PAA Becoming a substantial holder29/06/18
PAA Change of Director's Interest Notice - Bishop (re-release)27/06/18
PAA Change of Director's Interest Notice - Bishop27/06/18
PAA Change of Director's Interest Notice - Wright26/06/18
PAA Epichem Awarded Major US Drug Discovery Contract ExtensionPRICE SENSITIVE07/06/18
PAA MPL successfully reformulated for canine clinical trialsPRICE SENSITIVE28/05/18
PAA Chief Executive Officer resignsPRICE SENSITIVE21/05/18
PAA Appendix 4C & Company UpdatePRICE SENSITIVE01/05/18
PAA PharmAust enters option to license agreement with ElancoPRICE SENSITIVE18/04/18
PAA Trading HaltPRICE SENSITIVE16/04/18
PAA Wayne Best appointed Epichem Chairman and Dr Keenan as CEO10/04/18
PAA Cleansing Notice20/03/18
PAA Change of Director's Interest Notice x 316/03/18
PAA Appendix 3B & s708 notice16/03/18
PAA Collaboration with Olivia Newton-John Cancer Research Inst14/03/18
PAA Appendix 4D and Half Yearly Report & AccountsPRICE SENSITIVE28/02/18
PAA PharmAust receives $354k R&D Tax Incentive RefundPRICE SENSITIVE28/02/18
PAA Results of General Meeting26/02/18
PAA Appendix 4C - Quarterly Report & Shareholders UpdatePRICE SENSITIVE31/01/18
PAA Monepantel reformulation successfully improves dose & tastePRICE SENSITIVE30/01/18
PAA Notice of General Meeting/Proxy Form29/01/18
PAA Epichem Awarded One Year Contract Extension from DNDiPRICE SENSITIVE18/01/18
PAA International Vet Cancer Specialist Joins PAA Advisory Board18/12/17
PAA Appendix 3B & s708 notice14/12/17
PAA Phase II Dog Lymphoma Trial Confirms MPL Clinical BenefitPRICE SENSITIVE13/12/17
PAA PharmAust Raises $1.873m via an Oversubscribed PlacementPRICE SENSITIVE06/12/17
PAA Trading HaltPRICE SENSITIVE01/12/17
PAA Results of Annual General Meeting29/11/17
PAA PharmAust AGM Presentation29/11/17
PAA PharmAust Launches New Corporate Website29/11/17
PAA New MPL analogues show greater anti-cancer activityPRICE SENSITIVE23/11/17
PAA New drugs patented for cancer in USAPRICE SENSITIVE16/11/17
PAA Epichem Update - progress on milestones and revenue targetsPRICE SENSITIVE01/11/17
PAA Notice of Annual General Meeting/Proxy Form27/10/17
PAA Appendix 4C - Quarterly Report & Brief Company UpdatePRICE SENSITIVE26/10/17
PAA Monepantel reformulation project continues to progressPRICE SENSITIVE17/10/17
PAA New patent secured in US for non-cancer applicationsPRICE SENSITIVE10/10/17
PAA Two key appointments to bolster PharmAust vet drug programs03/10/17
PAA Reformulation project achieves first milestones and on-trackPRICE SENSITIVE20/09/17
PAA PharmAust secures core Europe patentPRICE SENSITIVE12/09/17
PAA PharmAust & Nihon Nohyaku Japan Enter Assignment AgreementPRICE SENSITIVE04/09/17
PAA Appendix 4G & Corporate Governance Statement01/09/17
PAA Appendix 4E & Full Year Statutory Accounts 2017PRICE SENSITIVE01/09/17
PAA PharmAust Investor Presentation30/08/17
PAA PharmAust Shareholders UpdatePRICE SENSITIVE22/08/17
PAA Appendix 4C - Quarterly Report & Brief Company UpdatePRICE SENSITIVE01/08/17
PAA Epichem reports record $3m revenues & expands laboratoryPRICE SENSITIVE17/07/17
PAA Canadian-based specialists to reformulate monepantelPRICE SENSITIVE27/06/17
PAA New European patent granted for non-cancer applicationsPRICE SENSITIVE08/06/17
PAA PharmAust secures core patent in JapanPRICE SENSITIVE06/06/17
PAA PharmAust Shareholders Update and Roadmap30/05/17
PAA PharmAust Investor Presentation - May 201722/05/17
PAA Phase II trial prelim results demonstrate clinical benefitPRICE SENSITIVE19/05/17
PAA New patent granted for non-cancer applicationsPRICE SENSITIVE17/05/17
PAA PharmAust secures core China patentPRICE SENSITIVE05/05/17
PAA Appendix 4C - Quarterly Report & Company Update - March 2017PRICE SENSITIVE13/04/17
PAA Dr Richard Mollard appointed as Chief Scientific Officer08/03/17
PAA PharmAust raises a further $534k03/03/17
PAA Dr Richard Hopkins Appointed as CEO of PharmAustPRICE SENSITIVE01/03/17
PAA Phase I Monepantel Tablets Demonstrate High Safety
28/03/19PRICE SENSITIVE
PAA PharmAust Raises $1.3m in Rights Issue
22/03/19PRICE SENSITIVE
PAA MPL Tablets Demonstrate Positive Performance in Phase 1
14/03/19PRICE SENSITIVE
PAA PharmAust Rights Issue Reaches Minimum Subscription
12/03/19PRICE SENSITIVE
PAA PharmAust Intellectual Property Update
05/03/19
PAA Appendix 4D & Financial Report
01/03/19PRICE SENSITIVE
PAA Offer Document - Rights Issue
26/02/19PRICE SENSITIVE
PAA Phase I Dog Trial with New Monepantel Tablets Commences
20/02/19PRICE SENSITIVE
PAA Letter to Shareholders
19/02/19
PAA Epichem Awarded One-Year Contract Extension from DNDi
18/02/19PRICE SENSITIVE
PAA Letter to Optionholders
18/02/19
PAA Section 708AA Notice
18/02/19
PAA Appendix 3B
18/02/19
PAA Non-Renounceable Rights Offer
18/02/19PRICE SENSITIVE
PAA Appendix 3B - Amendment
14/02/19
PAA PAA Completes Successful Taste Mask Testing of New Tablet
11/02/19PRICE SENSITIVE
PAA Section 708 Notice
07/02/19
PAA Appendix 3B
07/02/19
PAA PharmAust Signs Agreement for US Phase I Trials in Dogs
07/02/19PRICE SENSITIVE
PAA PharmAust Completes Scaled Manufacture of Monepantel Tablets
07/02/19PRICE SENSITIVE
PAA PharmAust Appendix 4C and Shareholders' Update
31/01/19PRICE SENSITIVE
PAA PharmAust and Elanco Execute Data Sharing Agreement
29/01/19PRICE SENSITIVE
PAA Optimisation of Monepantel Uptake
21/01/19PRICE SENSITIVE
PAA Monepantel Principal Metabolite Shows Anti-Cancer Activity
14/01/19PRICE SENSITIVE
PAA PharmAust Develops Method for MPL/Analogue Manufacture
03/12/18PRICE SENSITIVE
PAA GMP Tablet Manufacture Commences for Canine Clinical Trials
13/11/18PRICE SENSITIVE
PAA Results of Annual General Meeting
09/11/18
PAA AGM Presentation
09/11/18
PAA Appendix 4C & Company Update - Sep 2018
01/11/18PRICE SENSITIVE
PAA PharmAust Develops GMP Method for Monepantel Analogues
29/10/18PRICE SENSITIVE
PAA PharmAust Progresses Monepantel Tablet Program for Cancer
15/10/18PRICE SENSITIVE
PAA Notice of Annual General Meeting/Proxy Form
10/10/18
PAA Appendix 3X & 3Z
08/10/18
PAA Neville Bassett AM appointed to PharmAust Board
02/10/18
PAA Appendix 4G & Corporate Governance Statement
01/10/18
PAA Annual Report
01/10/18
PAA Olivia Newton-John Cancer Reseach Institute collaboration
10/09/18PRICE SENSITIVE
PAA Reformulation of MPL into tablet form for upcoming trials
04/09/18PRICE SENSITIVE
PAA Preliminary Final Report
03/09/18PRICE SENSITIVE
PAA Appendix 4C & Company Update - June 18
31/07/18PRICE SENSITIVE
PAA Epichem gains prestigious international ISO accreditation
02/07/18PRICE SENSITIVE
PAA Becoming a substantial holder
29/06/18
PAA Change of Director's Interest Notice - Bishop (re-release)
27/06/18
PAA Change of Director's Interest Notice - Bishop
27/06/18
PAA Change of Director's Interest Notice - Wright
26/06/18
PAA Epichem Awarded Major US Drug Discovery Contract Extension
07/06/18PRICE SENSITIVE
PAA MPL successfully reformulated for canine clinical trials
28/05/18PRICE SENSITIVE
PAA Chief Executive Officer resigns
21/05/18PRICE SENSITIVE
PAA Appendix 4C & Company Update
01/05/18PRICE SENSITIVE
PAA PharmAust enters option to license agreement with Elanco
18/04/18PRICE SENSITIVE
PAA Trading Halt
16/04/18PRICE SENSITIVE
PAA Wayne Best appointed Epichem Chairman and Dr Keenan as CEO
10/04/18
PAA Cleansing Notice
20/03/18
PAA Change of Director's Interest Notice x 3
16/03/18
PAA Appendix 3B & s708 notice
16/03/18
PAA Collaboration with Olivia Newton-John Cancer Research Inst
14/03/18
PAA Appendix 4D and Half Yearly Report & Accounts
28/02/18PRICE SENSITIVE
PAA PharmAust receives $354k R&D Tax Incentive Refund
28/02/18PRICE SENSITIVE
PAA Results of General Meeting
26/02/18
PAA Appendix 4C - Quarterly Report & Shareholders Update
31/01/18PRICE SENSITIVE
PAA Monepantel reformulation successfully improves dose & taste
30/01/18PRICE SENSITIVE
PAA Notice of General Meeting/Proxy Form
29/01/18
PAA Epichem Awarded One Year Contract Extension from DNDi
18/01/18PRICE SENSITIVE
PAA International Vet Cancer Specialist Joins PAA Advisory Board
18/12/17
PAA Appendix 3B & s708 notice
14/12/17
PAA Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
13/12/17PRICE SENSITIVE
PAA PharmAust Raises $1.873m via an Oversubscribed Placement
06/12/17PRICE SENSITIVE
PAA Trading Halt
01/12/17PRICE SENSITIVE
PAA Results of Annual General Meeting
29/11/17
PAA PharmAust AGM Presentation
29/11/17
PAA PharmAust Launches New Corporate Website
29/11/17
PAA New MPL analogues show greater anti-cancer activity
23/11/17PRICE SENSITIVE
PAA New drugs patented for cancer in USA
16/11/17PRICE SENSITIVE
PAA Epichem Update - progress on milestones and revenue targets
01/11/17PRICE SENSITIVE
PAA Notice of Annual General Meeting/Proxy Form
27/10/17
PAA Appendix 4C - Quarterly Report & Brief Company Update
26/10/17PRICE SENSITIVE
PAA Monepantel reformulation project continues to progress
17/10/17PRICE SENSITIVE
PAA New patent secured in US for non-cancer applications
10/10/17PRICE SENSITIVE
PAA Two key appointments to bolster PharmAust vet drug programs
03/10/17
PAA Reformulation project achieves first milestones and on-track
20/09/17PRICE SENSITIVE
PAA PharmAust secures core Europe patent
12/09/17PRICE SENSITIVE
PAA PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement
04/09/17PRICE SENSITIVE
PAA Appendix 4G & Corporate Governance Statement
01/09/17
PAA Appendix 4E & Full Year Statutory Accounts 2017
01/09/17PRICE SENSITIVE
PAA PharmAust Investor Presentation
30/08/17
PAA PharmAust Shareholders Update
22/08/17PRICE SENSITIVE
PAA Appendix 4C - Quarterly Report & Brief Company Update
01/08/17PRICE SENSITIVE
PAA Epichem reports record $3m revenues & expands laboratory
17/07/17PRICE SENSITIVE
PAA Canadian-based specialists to reformulate monepantel
27/06/17PRICE SENSITIVE
PAA New European patent granted for non-cancer applications
08/06/17PRICE SENSITIVE
PAA PharmAust secures core patent in Japan
06/06/17PRICE SENSITIVE
PAA PharmAust Shareholders Update and Roadmap
30/05/17
PAA PharmAust Investor Presentation - May 2017
22/05/17
PAA Phase II trial prelim results demonstrate clinical benefit
19/05/17PRICE SENSITIVE
PAA New patent granted for non-cancer applications
17/05/17PRICE SENSITIVE
PAA PharmAust secures core China patent
05/05/17PRICE SENSITIVE
PAA Appendix 4C - Quarterly Report & Company Update - March 2017
13/04/17PRICE SENSITIVE
PAA Dr Richard Mollard appointed as Chief Scientific Officer
08/03/17
PAA PharmAust raises a further $534k
03/03/17
PAA Dr Richard Hopkins Appointed as CEO of PharmAust
01/03/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
20.5¢ 		Change
0.005(2.50%) 		Mkt cap ! $82.69M
Open High Low Value Volume
20.5¢ 20.5¢ 20.0¢ $66.86K 327.5K

Buyers (Bids)

No. Vol. Price($)
3 27750 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
20.5¢ 84999 3
View Market Depth
Last trade - 14.42pm 27/09/2024 (20 minute delay) ?
Last
20.0¢ 		  Change
0.005 ( 0.00 %)
Open High Low Volume
20.5¢ 20.5¢ 20.0¢ 155684
Last updated 15.43pm 27/09/2024 ?
PAA (ASX) Chart

Top Stories

ACCC seeks Olam divestments before it can buy Namoi Cotton

Australia's market regulator the ACCC has expressed further concerns about the potential takeover of Namoi Cotton by Olam Agri.
HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico? De Grey Mining on Friday denied reports that it's received a takeover offer from Canada-based Agnico Eagle.
KalGold rolls out detailed aeromagnetic survey across Pinjin project Kalgoorlie Gold Mining Ltd has begun a high-resolution aeromagnetic geophysical survey across the northern parts of the Pinjin project
The market's shrugged at China's stimulus measures all year. Why is this one different? If you've been following the Chinese economy this year, you'd know that the country has been trying to stimulate all year.
5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core Strickland Metals Ltd has found an extensive zone of high-grade gold and base metals mineralisation at its Rogozna project
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.